Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein

Clinical Cancer Research

Volumn 20, Issue 15, 2014, Pages 4036-4046

  Veomett, Nicholas ^a,b   Dao, Tao ^a   Liu, Hong ^c   Xiang, Jingyi ^c   Pankov, Dmitry ^a   Dubrovsky, Leonid ^a   Whitten, Joseph A ^d   Park, Sun Mi ^a   Korontsvit, Tatyana ^a   Zakhaleva, Victoria ^a   Casey, Emily ^a   Curcio, Michael ^a   Kharas, Michael G ^a   O'Reilly, Richard J ^a   Liu, Cheng ^c   Scheinberg, David A ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c EUREKA THERAPEUTICS   (United States)

^d TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FC GAMMA RECEPTOR 4; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIB; FC RECEPTOR IIIA; IMMUNOGLOBULIN RECEPTOR; MONOCLONAL ANTIBODY ESK1; MONOCLONAL ANTIBODY ESKM; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; WT1 PROTEIN; EPITOPE; HLA A2 ANTIGEN; IMMUNOGLOBULIN FC FRAGMENT; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; MALE; MESOTHELIOMA; MESOTHELIOMA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA, EXPERIMENTAL; NONOBESE DIABETIC MOUSE; SCID MOUSE; TRANSGENIC MOUSE; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOTHERAPY; LEUKEMIA, EXPERIMENTAL; MALE; MESOTHELIOMA; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; WT1 PROTEINS;

EID: 84905460420     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2756     Document Type: Article

References (50)

1. Sensi M, Anichini A. Unique tumor antigens: evidence for immune control of genome integrity and immunogenic targets for T cell-mediated patient-specific immunotherapy. Clin Cancer Res 2006;12:5023-32.
2. Kessler JH, Melief CJ. Identification of T-cell epitopes for cancer immunotherapy. Leukemia 2007;21:1859-74.
3. Morris E, Hart D, Gao LQ, Tsallios A, Xue SA, Stauss H. Generation of tumor-specific T-cell therapies. Blood Rev 2006;20:61-9.
4. Konig R. Interactions between MHC molecules and co-receptors of the TCR. Curr Opin Immunol 2002;14:75-83.
5. Andersen PS, Stryhn A, Hansen BE, Fugger L, Engberg J, Buus S. A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Proc Natl Acad Sci U S A 1996;93:1820-4.
6. Epel M, Carmi I, Soueid-Baumgarten S, Oh SK, Bera T, Pastan I, et al. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies. Eur J Immunol 2008;38:1706-20.
7. Wittman VP, Woodburn D, Nguyen T, Neethling FA, Wright S, Weidanz JA. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death. J Immunol 2006;177:4187-95.
8. Klechevsky E, Gallegos M, Denkberg G, Palucka K, Banchereau J, Cohen C, et al. Antitumor activity of immunotoxins with T-cell receptorlike specificity against human melanoma xenografts. Cancer Res 2008;68:6360-7.
9. Bhattacharya R, Xu Y, Rahman MA, Couraud PO, Romero IA, Weksler BB, et al. A novel vascular targeting strategy for brain-derived endothelial cells using a TCR mimic antibody. J Cell Physiol 2010;225:664-72.
10. Verma B, Neethling FA, Caseltine S, Fabrizio G, Largo S, Duty JA, et al. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models. J Immunol 2010;184:2156-65.
11. Sergeeva A, Alatrash G, He H, Ruisaard K, Lu S, Wygant J, et al. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complementdependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood 2011;117:4262-72.
12. Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, et al. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Sci Transl Med 2013;5:176ra33.
13. Dao T, Scheinberg DA. Peptide vaccines for myeloid leukaemias. Best Pract Res Clin Haematol 2008;21:391-404.
14. Tanaka-Harada Y, Kawakami M, Oka Y, Tsuboi A, Katagiri T, Elisseeva OA, et al. Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies. Cancer Sci 2010;101:594-600.
15. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecolo Pathol 2008;27:161-74.
16. Raja S, Murthy SC, Mason DP. Malignant pleural mesothelioma. Curr Oncol Rep 2011;13:259-64.
17. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15:5323-37.
18. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071-9.
19. Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003;101:1698-704.
20. Desjarlais JR, Lazar GA, Zhukovsky EA, Chu SY. Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discov Today 2007;12:898-910.
21. Jefferis R. Glycosylation of recombinant antibody therapeutics. Biotechnol Prog 2005;21:11-6.
22. Hodoniczky J, Zheng YZ, James DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog 2005;21:1644-52.
23. De Romeuf C, Dutertre CA, Le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgRIIIA/CD16. Br J Haematol 2008;140:635-43.
24. Masuda K, Kubota T, Kaneko E, Iida S, Wakitani M, Kobayashi-Natsume Y, et al. Enhanced binding affinity for FcgRIIIa of fucosenegative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. Mol Immunol 2007;44:3122-31.
25. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcgRIII and antibody-dependent cellular toxicity. J Biol Chem 2002;277:26733-40.
26. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complextype oligosaccharides shows the critical role of enhancing antibodydependent cellular cytotoxicity. J Biol Chem 2003;278:3466-73.
27. Davies J, Jiang L, Pan LZ, La Barre MJ, Anderson D, Reff M. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcgRIII. Biotechnol Bioeng 2001;74:288-94.
28. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibodydependent cellular cytotoxic activity. Nat Biotechnol 1999;17:176-80.
29. Boyd PN, Lines AC, Patel AK. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 1995;32:1311-8.
30. Veomett N, Dao T, Scheinberg DA. Therapeutic antibodies to intracellular targets in cancer therapy. Expert Opin Biol Ther 2013;13:1485-8.
31. Lai L, Alaverdi N, Maltais L, Morse HC3rd. Mouse cell surfaceantigens: nomenclature and immunophenotyping. J Immunol 1998;160:3861-8.
32. Bosma MJ, Carroll AM. The SCID mouse mutant: definition, characterization, and potential uses. Annu Rev Immunol 1991;9:323-50.
33. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol 2005;174:6477-89.
34. Cox CV, Evely RS, Oakhill A, Pamphilon DH, Goulden NJ, Blair A. Characterization of acute lymphoblastic leukemia progenitor cells. Blood 2004;104:2919-25.
35. Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med 2007;9:1-17.
36. Center TUoTMDAC. Atlas of Laboratory Mouse Histology [cited 2012 June 13]. Available from: http://ctrgenpath.net/static/atlas/mousehistology/Windows/ introduction.html.
37. Cesta MF. Normal structure, function, and histology of the spleen. Toxicol Pathol 2006;34:455-65.
38. Kubota T, Niwa R, Satoh M, Akinaga S, Shitara K, Hanai N. Engineered therapeutic antibodies with improved effector functions. Cancer Sci 2009;100:1566-72.
39. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 2012;30:837-42.
40. Subramaniam JM, Whiteside G, McKeage K, Croxtall JC. Mogamulizumab: first global approval. Drugs 2012;72:1293-8.
41. Gasdaska JR, Sherwood S, Regan JT, Dickey LF. An afucosylated anti-CD20 monoclonal antibody with greater antibody-dependent cellular cytotoxicity and B-cell depletion and lower complement-dependent cytotoxicity than rituximab. Mol Immunol 2012;50:134-41.
42. Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, et al. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res 2010;70:4481-9.
43. Raghavan M, Bjorkman PJ. Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol 1996;12:181-220.
44. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007;7:715-25.
45. Allavena P, Chieppa M, Monti P, Piemonti L. From pattern recognition receptor to regulator of homeostasis: the double-faced macrophage mannose receptor. Crit Rev Immunol 2004;24:179-92.
46. Lee SJ, Evers S, Roeder D, Parlow AF, Risteli J, Risteli L, et al. Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science 2002;295:1898-901.
47. Stahl PD. The mannose receptor and other macrophage lectins. Curr Opin Immunol 1992;4:49-52.
48. Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 2011;21:949-59.
49. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood 2002;99:754-8.
50. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neupositive metastatic breast cancer. J Clin Oncol 2008;26:1789-96.